Five Prime Therapeutics, Inc. Doses First Cohort of Subjects in Phase 1 Study of FPA008
Published: Nov 01, 2013
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has completed dosing of the first cohort of healthy volunteer subjects in its Phase 1 clinical trial of FPA008. Five Prime is developing FPA008, its proprietary monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R), to treat patients with inflammatory diseases, including rheumatoid arthritis (RA). Five Prime is conducting the clinical trial initially in healthy volunteer subjects in the Netherlands under a Clinical Trial Application (CTA).
Help employers find you! Check out all the jobs and post your resume.